Partners

Scientific Committee

Andrea van Elsas became Chief Scientific Officer (CSO) in September 2017, following his tenure as Chief Scientific Officer of Aduro Biotech Europe since November 2015. Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.

http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2289408

Dr. Ignacio Melero has supervised eleven Ph.D. students of either gender and three graduate students are currently under his direct supervision. He is a full professor of Immunology at the University of Navarra and teaches in undergraduate and master degree courses. His experience as a Ph.D. thesis supervisor goes back to 1997.

Dr. Melero has clinical and translational duties, including being the principal investigator in 12 currently ongoing cancer immunotherapy clinical trials.

https://www.cun.es/nuestros-profesionales/profesionales/ignacio-javier-melero-bermejo

Dr. Pedro Berraondo completed his B.S. Degree in Pharmacy at the University of Navarra in 1999 and earned his Pharm.D. in drug design, synthesis, and evaluation from the University of Navarra in 2004. Dr. Berraondo carried out postdoctoral research at the Institut Pasteur in Paris. In 2007, he joined the program of Immunology and immunotherapy at the Center for Applied Medical Research (CIMA). Three Ph.D. students of either gender have been supervised by Pedro Berraondo and currently three graduate students are under his supervision.

https://cima.unav.edu/en/investigacion/programas-transversales/inmunologia-inmunoterapia/inmunologia-terapeutica/inmunoterapia-tumoral-basada-citoquinas/inmunoterapia-tumoral-basada-citoquinas/equipo

Dr. Dietmar Zaiss has been trained in different scientific systems, in Germany and the United States of America.

In The Netherlands, as group leader, he had more than 8 years experience in the supervision of 8 graduate students and successfully co-supervised four Ph.D. students. Since 2013, he holds a tenured Faculty position at the University of Edinburgh and is Chancellor’s Fellow. He currently supervises two Ph.D. students (one male one female) and several graduate students.

https://www.ed.ac.uk/profile/dietmar-zaiss